🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOther Peptides & Research CompoundsPeptide stability and storage — 12 month update Page 2

Peptide stability and storage — 12 month update

ZaraB_AL Mon, Jan 5, 2026 at 2:32 AM 17 replies 1,009 viewsPage 2 of 4
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jan 5, 2026 at 5:22 AM#6

KPV availability has improved over the past year. It used to be quite rare but more suppliers have added it as demand has increased. A few notes:

  • Available as lyophilized powder from select US peptide suppliers (5-10 mg vials)
  • Also available in oral capsule form from some supplement-adjacent companies
  • Being only three amino acids, it's relatively inexpensive to synthesize — expect $30-50 per 5 mg vial
  • Molecular weight: 342.43 Da — verify on CoA
  • HPLC purity should be ≥ 95% for a tripeptide (lower MW peptides can be harder to purify to 99%+ but 95% is acceptable)

The oral capsule products are probably more practical for most people, given the intended GI application. Look for products that specify the KPV content per capsule and ideally provide third-party testing.

12 4VanRx_Mike, steve_okc, dave_SLC and 9 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Jan 5, 2026 at 5:39 AM#7

I want to add one more research angle that's relevant. Xiao et al. (2015, PMID: 26192087) showed that α-MSH peptides (including KPV) could restore intestinal barrier integrity in models of inflammatory injury. This is significant because GLP-1 RAs can increase intestinal permeability in some individuals (often called "leaky gut," though that term is debated).

If KPV can tighten intestinal tight junctions while reducing NF-κB-mediated inflammation, it addresses two potential mechanisms by which GLP-1 RAs might exacerbate GI symptoms. That's a compelling stack rationale.

Obviously we need human data — all of this is preclinical. But among the anti-inflammatory peptides, KPV has one of the more coherent mechanistic stories for GI application.

11 20PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 8 others
Reply Quote Save Share Report
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
Jan 5, 2026 at 5:56 AM#8

Really appreciate this thread. I'm going to bring the Dalmasso PNAS paper to my next GI appointment and see if my doc is open to discussing it. Even if he's not, the safety profile of a naturally-occurring tripeptide seems very benign. Will report back. 🙏

46 13Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 43 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jan 5, 2026 at 6:13 AM#9

Good research-focused discussion. Reminder that IBD management should be supervised by a gastroenterologist — KPV is not a substitute for established IBD therapies. But it's encouraging to see this kind of mechanistic analysis applied to peptides that could genuinely help a subset of our community.

6 17BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 3 others
Reply Quote Save Share Report

Similar Threads

BPC-157 oral vs injectable — bioavailability review and evidence15 replies
TB-500 for tissue repair — mechanism and clinical evidence4 replies
Selank and Semax — anxiolytic peptides overview2 replies
CJC-1295/Ipamorelin combination — GH secretagogue discussion23 replies
BPC-157 + GLP-1 stacking for gut healing — N=1 experience17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register